Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma
Cancer, 08/03/09
Chou AJ et al. - In a study to examine the addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) to chemotherapy for pts with metastatic osteosarcoma (OS), it was found that when the metastatic cohort was considered in isolation, addition of liposomal MTP-PE to chemotherapy did not achieve a statistically significant improvement in outcome. But the pattern of outcome is similar to the pattern in nonmetastatic pts.
Methods- Intergroup-0133 was a prospective randomized phase 3 trial for the treatment of newly diagnosed pts with OS.
- 3-drug chemotherapy with cisplatin, doxorubicin, and high-dose methotrexate (Regimen A) was compared with the same 3 drugs with the addition of ifosfamide (Regimen B).
- Addition of liposomal MTP-PE to chemotherapy was evaluated.
- 5-yr event-free survival (EFS) for pts who received liposomal MTP-PE (n=46) was 42% vs 26% for those who did not (n=45).
- 5-yr overall survival for pts who received MTP-PE vs no MTP-PE was 53% and 40%, respectively.
- The comparison of Regimen A with Regimen B did not suggest a difference for EFS (35% vs 34%, respectively) or overall survival (52% vs 43%, respectively).
Related Articles
Caffeine-potentiated chemotherapy for metastatic osteosarcoma
Journal of Orthopaedic Science, 10/06/09
Relevance Score: 65%
Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients
Journal of Cancer Research & Clinical Oncology, 10/01/09
Relevance Score: 65%
Gene expression profiling of primary and metastatic colon cancers identifies a reduced proliferative rate in metastatic tumors
Clinical and Experimental Metastasis, 11/05/09
Relevance Score: 46%
Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy
The Oncologist, 10/30/09
Relevance Score: 46%
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09
Relevance Score: 45%
Today in Bone/Cartilage...keeping you current
Receive free subspecialty "5-minute updates" via email
mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients prognosis
Medical Oncology, 12/04/09
Oleanolic acid derivative Dex-OA has potent anti-tumor and anti-metastatic activity on osteosarcoma cells in vitro and in vivo
Investigational New Drugs, 12/04/09
Interventional radiology procedures in the treatment of bone metastasis
Bulletin du Cancer, 12/01/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


